MedPath

Tagged News

DaltonTx Emerges from Stealth with £4M Seed Funding to Transform Drug Discovery with Adaptive AI Platform

AIDrug Discovery
  • DaltonTx, a UK-based technology company, has completed a £4 million seed financing round to develop adaptive AI-enabled discovery platforms that reshape R&D economics and timelines.
  • The company's disease- and technology-agnostic platform integrates directly into pharma, biotech, and CRO workflows, providing immediate access to AI-enabled discovery capabilities.
  • Founded by experts from AstraZeneca, Exscientia, and Oxford University, DaltonTx offers a reasoning engine that learns from every scientist, model, and experiment to continuously improve outcomes.
  • The platform supports both small molecules and biologics discovery, enabling collaborative intelligence between human expertise and machine learning systems.

Healx Partners with Vuja De Sciences to Advance AI-Driven Therapy for Metastatic Osteosarcoma Recurrence

AIRare DiseaseDrug Discovery
  • Healx has entered into a strategic transaction with Vuja De Sciences to combine AI-powered drug discovery with clinical expertise in cancer recurrence prevention.
  • The partnership advances HLX-4310, a promising therapy for preventing recurrence of metastatic osteosarcoma that has received FDA IND clearance for clinical trials.
  • Metastatic osteosarcoma affects mostly young patients with a devastating five-year survival rate of less than 20%, representing a critical unmet medical need.
  • The collaboration strengthens Healx's rare and pediatric oncology portfolio, now advancing two clinical-stage assets in this therapeutic area.

Merck and Siemens Expand Partnership to Accelerate AI-Driven Drug Discovery and Manufacturing

AIDrug Discovery
  • Merck and Siemens signed a new Memorandum of Understanding to deliver integrated digital workflows connecting drug discovery, development, and manufacturing through AI and automation technologies.
  • The partnership will integrate Merck's software-as-a-service products with Siemens' digital ecosystem, including the first joint use of technology from Siemens' recent Dotmatics acquisition completed in July 2025.
  • Initial pilot projects focus on making Merck's AI tools available in Siemens' Luma platform, providing scientists with a unified environment for faster, data-driven decision making.
  • The collaboration aims to address the escalating costs of drug development, which double every few years, by leveraging digitalization and AI to streamline processes from laboratory to patient.

GeneDx Strengthens Leadership Team with Key Appointments to Advance AI-Powered Precision Medicine

AIPrecision MedicineRare DiseaseDrug Discovery
  • GeneDx appointed Lisa Gurry as Chief Business Officer to lead strategic partnerships and unlock the potential of GeneDx Infinity, the world's largest rare disease dataset with nearly one million exomes and genomes.
  • The company also named Dr. Thomas Fuchs, Chief AI Officer at Eli Lilly, to its board of directors to advance AI applications in genomic medicine and drug discovery.
  • These appointments position GeneDx to accelerate precision medicine initiatives, leveraging AI tools like Multiscore and recent acquisitions such as Fabric Genomics to improve diagnostic efficiency.
  • The strategic moves aim to enhance partnerships with biopharma companies and health systems while delivering faster, more accurate rare disease diagnoses for patients and families.

Alnylam Pharmaceuticals Joins Alliance for Genomic Discovery to Accelerate RNAi Drug Development

Precision MedicineDrug Discovery
  • Alnylam Pharmaceuticals has joined the Alliance for Genomic Discovery as the ninth member, gaining access to a comprehensive clinical genomic database containing 250,000 whole-genomes to accelerate RNA interference therapeutic development.
  • The partnership will enable Alnylam to leverage AI-powered genomic data to identify new therapeutic targets for gene silencing medicines, with the alliance expanding to include an additional 31,250 whole-genomes.
  • The AGD dataset has already demonstrated value by identifying novel therapeutic targets in autoimmune and neurodegenerative diseases, with plans to add multiomic layers including proteomics to enhance drug discovery capabilities.

Enveric Biosciences Publishes Breakthrough Research on Microbial Bioproduction of Neuropsychiatric Compounds

Drug Discovery
  • Enveric Biosciences published two peer-reviewed papers in ACS Chemical Biology and BioDesign Research describing innovative microbial bioproduction methods for neuropsychiatric drug discovery.
  • Researchers successfully engineered microbial systems to produce 279 tryptamine derivatives, including 17 novel N-acetylated molecules that showed activity across psychiatric disease-linked receptors.
  • The team developed the first bioproduction method for MDMA and derivatives using engineered yeast, providing an alternative to traditional chemical synthesis that relies on controlled precursor materials.
  • These advances expand the toolkit for neuroplastogen drug discovery while Enveric advances its lead candidate EB-003 toward IND submission and first-in-human studies anticipated in 2026.

Dualitas Therapeutics Emerges from Stealth with $65M Series A to Advance Bispecific Antibody Pipeline

Drug Discovery
  • Dualitas Therapeutics launched from stealth with $65 million Series A funding co-led by Versant Ventures and Qiming Venture Partners USA, with participation from Eli Lilly and Company and other strategic investors.
  • The company's lead programs DTX-103 for allergic disease and DTX-102 for autoimmune disease have demonstrated compelling preclinical profiles when benchmarked against commercially available therapies.
  • Dualitas' proprietary DualScreen discovery engine functionally screens entire cell surfaces to identify bispecific antibody combinations with truly synergistic rather than simply additive effects.
  • The funding will advance the bispecific antibody pipeline and accelerate development of the DualScreen platform to expand into broader therapeutic areas including cancer and rare diseases.

Drug Hunter Secures Seed Investment to Expand Knowledge Platform for Pharmaceutical R&D

Drug Discovery
  • Drug Hunter, a knowledge platform serving over 200 pharmaceutical R&D organizations including Eli Lilly, Biogen, and NIH, announced seed funding led by Teamworthy Ventures to accelerate drug discovery insights.
  • The platform provides searchable insights from scientific literature, patents, and early disclosures, helping researchers make better-informed decisions and avoid costly mistakes in drug development.
  • Industry leaders from Isomorphic Labs, Biogen, and other major organizations describe Drug Hunter as an indispensable tool for accelerating decision-making and surfacing novel ideas.
  • The funding will support expanded scientific coverage, enhanced chemical structure databases, improved search analytics tools, and development of a mobile application for immediate disclosure highlights.

Lila Sciences Achieves Unicorn Status with $235M Funding for AI-Driven Drug Discovery Platform

AIDrug Discovery
  • Lila Sciences secured $235 million in funding, achieving unicorn status with a valuation exceeding $1 billion for its AI-powered drug discovery platform.
  • The Cambridge-based startup is developing the world's first "scientific superintelligence" platform that combines advanced AI models with fully autonomous robotic laboratories.
  • Founded this year with initial $200 million seed funding from Flagship Pioneering, the company aims to revolutionize drug development by automating the entire scientific workflow.
  • Led by CEO Geoffrey von Maltzahn and Chief Scientist George Church from Harvard, Lila's closed-loop system promises to drastically reduce time and costs in drug development.

AMD Partners with Oracle and Absci to Accelerate AI-Driven Drug Discovery Using Advanced GPU Technology

AIDrug Discovery
  • Advanced Micro Devices has formed a strategic collaboration with Oracle Cloud Infrastructure and Absci to advance AI-driven drug discovery using its cutting-edge Instinct MI355X GPUs.
  • The partnership positions AMD to capitalize on the growing intersection of artificial intelligence and pharmaceutical research, potentially enhancing its market position in high-performance computing sectors.
  • AMD's stock has shown strong performance with a 34-35% increase over the last quarter, supported by strategic partnerships and positive market sentiment around AI adoption in healthcare.
  • Despite geopolitical challenges and export restrictions, analysts maintain a consensus price target of $185.77, suggesting potential upside from current trading levels around $155-160.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.